PMID- 30477860
OWN - NLM
STAT- MEDLINE
DCOM- 20190308
LR  - 20221207
IS  - 1873-6963 (Electronic)
IS  - 0965-2299 (Linking)
VI  - 41
DP  - 2018 Dec
TI  - The effects of silymarin supplementation on metabolic status and oxidative stress 
      in patients with type 2 diabetes mellitus: A systematic review and meta-analysis 
      of clinical trials.
PG  - 311-319
LID - S0965-2299(18)30547-8 [pii]
LID - 10.1016/j.ctim.2018.08.010 [doi]
AB  - OBJECTIVE: The effect of silymarin supplementation on metabolic status and 
      oxidative stress of subjects with type 2 diabetes mellitus (T2DM) has not been 
      conclusively studied. Therefore, the efficacy of silymarin supplementation in 
      these patients was assessed through a meta-analysis. METHODS: The following 
      databases were searched up to May 15, 2018: PubMed, Scopus, Ovid (Cochrane 
      library), Google scholar and ISI web of science. All randomized clinical trials 
      using silymarin supplements to improve T2DM included in this meta-analysis. Mean 
      Difference (MD) was pooled using a random-effects model. RESULTS: Eight eligible 
      publications from seven trials were identified for the present meta-analysis. Our 
      results revealed that supplementation with silymarin can decrease fasting blood 
      sugar, hemoglobin A1C, insulin, low-density lipoprotein cholesterol and 
      malondialdehyde and increase high-density lipoprotein cholesterol levels. 
      However, silymarin did not have any significant effects on total cholesterol or 
      triglyceride concentrations. CONCLUSION: Our data suggest that silymarin 
      supplements have beneficial effects on metabolic status and oxidative stress 
      among patients with T2DM. However, there is currently insufficient evidence to 
      make firm conclusions about the full efficacy of supplementation.
CI  - Copyright (c) 2018. Published by Elsevier Ltd.
FAU - Hadi, Amir
AU  - Hadi A
AD  - Students' Research Committee, Department of Clinical Nutrition, School of 
      Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, 
      Iran.
FAU - Pourmasoumi, Makan
AU  - Pourmasoumi M
AD  - Gastrointestinal & Liver Diseases Research Center (GLDRC), Guilan University of 
      Medical Sciences, Rasht, Iran.
FAU - Mohammadi, Hamed
AU  - Mohammadi H
AD  - Students' Research Committee, Department of Clinical Nutrition, School of 
      Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, 
      Iran. Electronic address: Mohamadihd@gmail.com.
FAU - Symonds, Michael
AU  - Symonds M
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran e Early Life Research Unit, Division of Child Health, Obstetrics & 
      Gynaecology, School of Medicine, University of Nottingham, Nottingham, UK; 
      Nottingham Digestive Disease Centre and Biomedical Research Centre, School of 
      Medicine, University of Nottingham, Nottingham, UK.
FAU - Miraghajani, Maryam
AU  - Miraghajani M
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran e Early Life Research Unit, Division of Child Health, Obstetrics & 
      Gynaecology, School of Medicine, University of Nottingham, Nottingham, UK; Cancer 
      Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
      Electronic address: ms.miraghajani@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180903
PL  - Scotland
TA  - Complement Ther Med
JT  - Complementary therapies in medicine
JID - 9308777
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (Silymarin)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Insulin/blood
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Silymarin/*pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Lipid profile
OT  - Oxidative stress
OT  - Silymarin
OT  - T2DM
EDAT- 2018/11/28 06:00
MHDA- 2019/03/09 06:00
CRDT- 2018/11/28 06:00
PHST- 2018/06/10 00:00 [received]
PHST- 2018/06/28 00:00 [revised]
PHST- 2018/08/24 00:00 [accepted]
PHST- 2018/11/28 06:00 [entrez]
PHST- 2018/11/28 06:00 [pubmed]
PHST- 2019/03/09 06:00 [medline]
AID - S0965-2299(18)30547-8 [pii]
AID - 10.1016/j.ctim.2018.08.010 [doi]
PST - ppublish
SO  - Complement Ther Med. 2018 Dec;41:311-319. doi: 10.1016/j.ctim.2018.08.010. Epub 
      2018 Sep 3.